Drug-Associated Delirium Identified in The Food and Drug Administration Adverse Events Reporting System

• DOI: 10.31487/j.pdr.2019.03.01
• Publication Date: 2019-08-16T05:55:14Z
• Authors: Adrian Wong; Angela Li; Kane Gill; Matthew P. Gray; Pamela L. Smithbu...; Seohyun Claudia Choi
• Keywords: Akathisia

Introduction: Drug toxicity and polypharmacy are major risk factors for delirium, especially in older adult patients with underlying comorbidities. However, numerous case reports have described drugs a lower suspicion of being deliriogenic. The objective this study was to identify deliriogenic the Food Administration Adverse Events Reporting System (FAERS) broaden public knowledge understanding. Study Design: Retrospective pharmacovigilance evaluation. Methods: FAERS from 2004 through 2015 were reviewed delirium-associated terms, which utilized most frequently reported cause delirium. Drugs categorized as: 1) known be deliriogenic; 2) potentially or 3) new potential 100 analyzed reporting odds ratios (ROR). Results: Of (n=32), paroxetine (ROR 4.1, CI 4.0-4.3), olanzapine 3.3, 3.2-3.4), clozapine 2.9, 2.8-3.0) reported. (n=54), duloxetine 3.2, 3.1-3.3), varenicline 3.1, 3.0-3.2), gabapentin 2.7-3.0) Three considered deliriogenic: heparin 1.5, 1.4-1.6), metformin 1.3, 1.3-1.4), dalfampridine 1.1, 1.1-1.2). Conclusion: majority can provide post-marketing surveillance data guide future studies on management causal agents.